Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide add-on therapy for refractory focal seizures in children
IRCT20211104052968N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lacosamide in Focal Onset Epilepsy, sponsored by Isfahan University of Medical Sciences. Primary endpoint: Efficacy of lacosamide as add-on therapy in refractory focal seizures. Started Feb 2021; status: completed.
02
Drugs
lacosamide
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on IRCT20211104052968N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211104052968N1.